Pfizer explores sale of hospital drugs unit, sources say
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in ...
Pfizer (PFE) has been on a downward spiral lately with significant selling pressure. After declining 11% over the past four ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
Pfizer (PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, Reuters’ ...
Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...
Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...
Keurig Dr Pepper brings in Drew Panayiotou to accelerate digital marketing and Andrew Springate takes a new role.
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback